Catalent, Inc. (NYSE:CTLT) Shares Purchased by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Catalent, Inc. (NYSE:CTLT) by 166.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,382,424 shares of the company’s stock after purchasing an additional 863,624 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Catalent were worth $83,733,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. BNP Paribas Financial Markets grew its stake in shares of Catalent by 9.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 267,219 shares of the company’s stock worth $16,185,000 after purchasing an additional 22,785 shares during the last quarter. Brooklyn Investment Group acquired a new position in shares of Catalent in the 3rd quarter worth approximately $31,000. Quantbot Technologies LP acquired a new position in shares of Catalent in the 3rd quarter worth approximately $7,222,000. FMR LLC grew its stake in shares of Catalent by 4.8% in the 3rd quarter. FMR LLC now owns 265,369 shares of the company’s stock worth $16,073,000 after purchasing an additional 12,241 shares during the last quarter. Finally, Bank of Montreal Can grew its stake in shares of Catalent by 181.5% in the 3rd quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock worth $109,388,000 after purchasing an additional 1,169,044 shares during the last quarter.

Insider Activity

In other news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now owns 10,835 shares of the company’s stock, valued at $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,114 shares of company stock valued at $305,931 over the last 90 days. 0.31% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CTLT. StockNews.com cut shares of Catalent from a “hold” rating to a “sell” rating in a research note on Friday, November 22nd. William Blair restated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Finally, Robert W. Baird reiterated a “neutral” rating and issued a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. One analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $63.40.

Catalent Price Performance

NYSE CTLT opened at $60.76 on Wednesday. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The stock has a market capitalization of $11.03 billion, a PE ratio of -26.88, a price-to-earnings-growth ratio of 2.44 and a beta of 1.16. The company has a 50 day moving average price of $59.84 and a two-hundred day moving average price of $58.39. Catalent, Inc. has a 12-month low of $36.74 and a 12-month high of $61.50.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the prior year, the business earned ($0.10) EPS. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. As a group, equities analysts predict that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.